Areas of Focus
- 小分子药物设计与合成
Work Experience
- 2014-11~2019-02 - 密歇根大学-安娜堡校区 - 博士后
- 2009-09~2014-07 - 中国科学院广州生物医药与健康研究院 - 研究生/博士
- 2005-09~2009-06 - 山东师范大学 - 本科/学士
Academic Background & Achievements
- 2009-09--2014-07 博士: 中国科学院广州生物医药与健康研究院
- 2005-09--2009-06 学士: 山东师范大学
Publications
- Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC degraders of Oncogenic KRASG12D, 徐田锋, 2024
- Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Associate Domain (TEAD) PROTAC Degraders, 徐田锋, 2024
- Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers, 徐田锋, 2023
- Design, Synthesis, and Bioevaluation of Pyrido2,3-dpyrimidin-7-ones as Potent SOS1 Inhibitors, 徐田锋, 2023
- Design, synthesis and structure-activity relationship studies of pyrido2,3-dpyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors, 徐田锋, 2022
- Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations, 徐田锋, 2022
- Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation, 徐田锋, 2022
- Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, 徐田锋, 2019
- Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, 徐田锋, 2018
- A structure-guided optimization of pyrido2,3-dpyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties, 徐田锋, 2017
- C5-substituted pyrido2,3-dpyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant, 徐田锋, 2015
- Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as Selective Inhibitors of EGFR Threonine790—Methionine790 (T790M) Mutants., 徐田锋, 2013
- Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, 徐田锋, 2013
- Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, 徐田锋, 2013
- Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, 徐田锋, 2012
Awards
- 广东省科学技术奖励 (2016): 二等奖
- 广州市科学技术奖励 (2015): 一等奖
